ADDISON, Texas, April 5 /PRNewswire-FirstCall/ -- ULURU Inc. today announced that Jeffrey A. Stone, D.O., M.P.H., FCCWS has been appointed to serve on the Company’s Board of Directors.
Dr. Stone not only has extensive experience in the treatment of chronic wounds but has also been involved in both Medicare and Medicaid in Texas, on the editorial advisory board and as a reviewer for wound care journals and with a health insurance company. He has also held the position of medical director of the wound care programs at numerous hospitals and long-term acute care facilities throughout the Dallas metroplex.
Commenting on the appointment, Renaat Van den Hooff, President and CEO stated, “We are pleased to have a recognized medical practitioner with vast wound care experience such as Dr. Stone joining our Board. His extensive clinical experience directing wound care programs and managing wound care clinics will be invaluable as we continue commercializing Altrazeal(TM). We very much look forward to his contributions to help us build a successful wound care business.”
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the value of our products in the marketplace, our ability to develop and market our technologies and commercialization of products in the marketplace. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by us with the Securities and Exchange Commission.
ULURU Inc.
